Trial Profile
Are early and late cardiovascular risk markers in women with polycystic ovary syndrome (PCOS) increased with concomitant non-alcoholic steatohepatitis (NASH) and can this be modified with exenatide?: An interventional open parallel single-centre trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Polycystic ovary syndrome
- Focus Pharmacodynamics
- 30 Sep 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 27 May 2009 New trial record